Long-term follow-up of patients with adenocarcinoma of the Esophagus treated with perioperative chemotherapy (FLOT Protocol) or neoadjuvant chemoradiation (CROSS Protocol) (ESOFU Observational Study)

Long-term follow-up of patients with adenocarcinoma of the Esophagus treated with perioperative chemotherapy (FLOT Protocol) or neoadjuvant chemoradiation (CROSS Protocol) (ESOFU Observational Study) - ESOFU

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032782

Enrollment

145

Registered

2026-07-31

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C15

Interventions

Group 1: After inclusion in the study, the subjects will be contacted via telefphone once a year to assess overall survival and tumor progression. Annual follow-up visits are carried out until 7 years

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Participation in the ESOPEC trial 2. Ability to understand character and individual consequences of the study 3. Written informed consent has been obtained

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The patient’s overall survival, as the primary time-to-event endpoint, is assessed and documented through annual telephone consultations.	—

Secondary

Measure	Time frame
During the annual telephone visits, progression-free survival and recurrence-free survival – both of which are secondary time-to-event endpoints – are also recorded and documented.	—

Countries

Germany

Contacts

Public ContactJens Höppner

Universitätsklinikum OWL der Universität Bielefeld – Campus Lippe

Jens.Hoeppner@klinikum-lippe.de05231-722134

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026